Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

Conditions: Gram Negative Pneumonia; Gram-Negative Bacterial Infections; Bacteremia Caused by Gram-Negative Bacteria Interventions: Drug: Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day; Other: Placebo Sponsors: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials